Decentralised clinical trial services to help you reach more patients faster
Overcoming traditional trial barriers
Bringing a new therapy to market is expensive, complex and time-sensitive. Traditional site-based trials can slow progress with limited patient reach, high dropout rates and rising operational costs.
By partnering with Sciensus, biopharma companies gain the confidence of working with an established provider that helps deliver studies faster, at scale and with better patient outcomes.
Accelerated recruitment and retention
Improved data quality
Cost efficiency and scalability
Enhance and accelerate reach of your clinical trials
Sciensus delivers a fully integrated DCT service as all our staff have GCP training. From home-based patient care by Sciensus nurses and secure IMP holding and distribution to regulatory-compliant trial management. Our approach ensures every patient receives treatment safely, on time and with minimal disruption to their daily lives. We also capture all this evidence in ready to use formats.
Turn trial participation into long-term evidence generation
Clinical trials are often the start of a much longer evidence journey. Sciensus combines decentralised trial support, patient engagement and real-world data collection to help sponsors generate insights throughout development, launch and commercialisation.
By engaging patients directly through nurse-led services, digital tools and ongoing monitoring, we help transform clinical interactions into evidence that supports regulatory, HTA and market access decision-making.
-
Home and remote patient visits
-
Digital patient engagement
-
Specialist pharmacy and logistics
Turn dropout challenges into retention success
Get in touch to see how integrated homecare, digital tools and specialist logistics keep patients engaged.
Sciensus is a leader in decentralised clinical trial services across Europe, supporting Phase II–IV studies, insight research and early access schemes. Our unique model combines home-based nursing care, advanced digital platforms and specialist pharmacy services to create a seamless patient and sponsor experience.
With our GDP-compliant distribution network and expertise in handling IMPs at all temperature ranges, we enable safe and efficient trial execution. Our integrated solutions ensure regulatory compliance, enhance data integrity and reduce operational complexity.
By partnering with Sciensus, pharma and biotech companies gain the confidence of working with an established provider that helps deliver studies faster, at scale and with better patient outcomes.
Improved retention through improved patient experience
Customisable end-to-end clinical solutions
Time-proven European network
Frequently asked questions
How does Sciensus support clinical trials?
Clinical trials provide critical evidence on safety and efficacy in controlled environments. Decentralised trials designs aim to make access and participation easier for patients. Sciensus can deliver this by engaging patients directly through our home-based services and digital tools. We help generate the study data needed to progress clinical development.
In addition, Sciensus helps sponsors extend the clinical trial evidence base into real-world settings. Through a combination of real world non interventional studies, patient support programmes, patient engagement and remote monitoring we can generate real world insights, longitudinal evidence on treatment use, patient experience and outcomes. These data complement clinical trial data and support regulatory, market access and commercial decision-making throughout the product lifecycle.
How does Sciensus support decentralised clinical trials?
We provide support services, including home GCP trained nurse visits, IMP logistics, digital platforms and data collection all in a regulatory compliant framework.
What are the advantages of direct-to-patient clinical trials?
They remove barriers to participation, improve recruitment of diverse populations and reduce dropout rates by minimising patient travel.
Can Sciensus customise a DCT solution for my study?
Yes, our services are fully customisable to your study’s size, scope and therapeutic area. We tailor trial models to meet sponsor, patient and regulatory requirements.
Can trial participants continue in evidence generation programmes after a study ends?
Where appropriate and permitted within the study design and regulatory requirements, sponsors may choose to continue gathering insights beyond a clinical trial through activities such as patient support programmes, non-interventional studies including post-authorisation studies and other evidence generation initiatives.
Sciensus supports programmes across the development and commercialisation journey, helping sponsors maintain continuity of patient engagement and generate longitudinal real-world insights that can inform launch planning, market access activities and post-marketing evidence requirements.
What types of data can Sciensus collect?
The data collected depends on the programme design, protocol and regulatory requirements. Sciensus can support the collection of a broad range of real-world data and patient insights, including treatment adherence, medication usage, symptoms, patient-reported outcomes (PROs), patient-reported experience measures (PREMs), patient experience data, safety information and other study-specific measures.
Data can be gathered through digital platforms, remote monitoring, in-home clinical services and non-interventional research programmes, helping sponsors develop a deeper understanding of how therapies perform in routine clinical practice.
Meet our clinical trials expert
Get in touch
Thank you for your interest in Sciensus. Whether you’re seeking information, partnership opportunities, or want to refer a patient, our dedicated team is here to assist you. Please fill out the form on the right, and one of our multi-lingual representatives will get in touch with you promptly.